MUMBAI, India and NAPLES, Fla., April 7, 2026
Lupin Limited has received approval from the U.S. Food and Drug Administration (FDA) for its Dapagliflozin Tablets (5 mg and 10 mg), marking a significant milestone in expanding its diabetes and cardiometabolic portfolio in the United States. The approval confirms that Lupin’s product is bioequivalent to the reference drug Farxiga®, enabling its use for the same approved indications and strengthening access to cost-effective treatment options.
FDA Approval Strengthens Generic Diabetes Portfolio
The approval was granted under an Abbreviated New Drug Application (ANDA) pathway, allowing Lupin to introduce a generic version of dapagliflozin, a widely used SGLT2 inhibitor for type 2 diabetes and cardiovascular risk management. This regulatory milestone reinforces Lupin’s strategy to expand its footprint in the U.S. generics market, particularly in high-demand therapeutic areas such as diabetes and heart disease.
Dapagliflozin is an important oral therapy that works by inhibiting sodium-glucose co-transporter 2 (SGLT2), reducing glucose reabsorption in the kidneys and lowering blood sugar levels. Beyond glycemic control, the drug has demonstrated cardiovascular and renal benefits, making it a critical component in modern diabetes management.
By offering a bioequivalent and cost-effective alternative, Lupin’s approval is expected to improve patient access to essential therapies, especially in markets where affordability and availability remain key challenges.
Advertisement
Expanding Access to Advanced Cardiometabolic Therapies
The approval of dapagliflozin tablets highlights the growing importance of SGLT2 inhibitors in treating not only diabetes but also heart failure and chronic kidney disease, reflecting a shift toward multi-benefit therapies in cardiometabolic care. These drugs are increasingly recognized for their ability to reduce hospitalization risk and improve long-term patient outcomes, positioning them as a cornerstone of treatment guidelines.
Lupin’s entry into this segment aligns with global healthcare trends emphasizing integrated disease management and preventive care, where a single therapeutic agent can address multiple comorbid conditions. This approach is particularly relevant as the prevalence of type 2 diabetes and associated cardiovascular complications continues to rise globally.
Additionally, the company’s strong manufacturing and regulatory capabilities enable it to deliver high-quality pharmaceutical products that meet stringent FDA standards, ensuring safety, efficacy, and consistency in supply.
Strategic Growth in the U.S. Pharmaceutical Market
The U.S. remains one of the most competitive and lucrative pharmaceutical markets, and this approval further strengthens Lupin’s position as a global leader in generic and specialty pharmaceuticals. With a diverse portfolio spanning multiple therapeutic areas, the company continues to leverage its research, manufacturing, and regulatory expertise to drive growth and innovation.
Lupin’s focus on expanding its generics pipeline, combined with its investments in complex generics, biotechnology products, and digital health solutions, reflects a long-term strategy aimed at delivering comprehensive healthcare solutions. The approval of dapagliflozin tablets adds to its growing portfolio of anti-diabetic and cardiovascular therapies, supporting its mission to improve patient health outcomes worldwide.
Furthermore, this milestone demonstrates Lupin’s ability to navigate complex regulatory pathways and bring high-value, clinically relevant products to market efficiently, reinforcing its competitive position in the global pharmaceutical landscape.
The U.S. FDA approval of Lupin’s dapagliflozin tablets represents a major advancement in expanding access to essential diabetes and cardiometabolic therapies, offering patients a cost-effective and clinically validated treatment option. With strong regulatory backing and a focus on innovation, Lupin continues to play a vital role in addressing the growing burden of chronic diseases through high-quality pharmaceutical solutions.
Source: Lupin press release
